Wall Street brokerages expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to announce ($0.13) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). ZIOPHARM Oncology reported earnings per share of ($0.11) during the same quarter last year, which suggests a negative year over year growth rate of 18.2%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.54). For the next year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.53). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The company’s revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.01) EPS.

A number of research analysts have issued reports on ZIOP shares. ValuEngine lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $13.17.

Several institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of ZIOPHARM Oncology by 8.2% in the second quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock valued at $649,000 after buying an additional 7,946 shares during the period. State Street Corp lifted its holdings in shares of ZIOPHARM Oncology by 12.8% in the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after buying an additional 517,057 shares during the period. Tudor Investment Corp ET AL lifted its holdings in shares of ZIOPHARM Oncology by 390.4% in the second quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock valued at $394,000 after buying an additional 50,395 shares during the period. Voya Investment Management LLC lifted its holdings in shares of ZIOPHARM Oncology by 21.9% in the second quarter. Voya Investment Management LLC now owns 60,782 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 10,913 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of ZIOPHARM Oncology by 6.0% in the second quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 4,826 shares during the period. Institutional investors and hedge funds own 41.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “-$0.13 EPS Expected for ZIOPHARM Oncology Inc (ZIOP) This Quarter” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/17/0-13-eps-expected-for-ziopharm-oncology-inc-ziop-this-quarter.html.

ZIOPHARM Oncology (NASDAQ ZIOP) opened at 6.21 on Friday. The stock’s market cap is $873.32 million. The firm has a 50-day moving average price of $5.82 and a 200 day moving average price of $6.25. ZIOPHARM Oncology has a 52-week low of $4.84 and a 52-week high of $7.88.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.